Triglycerides and cardiovascular disease

The Lancet

Volumn 384, Issue 9943, 2014, Pages 626-635

  Nordestgaard, Børge G ^a,b   Varbo, Anette ^a,b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LIPOPROTEIN; TRIACYLGLYCEROL; ANTILIPEMIC AGENT; APOLIPOPROTEIN C3 INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DIACYLGLYCEROL ACYLTRANSFERASE 1 INIHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEW DRUG; OMEGA 3 FATTY ACID INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PROTEIN INHIBITOR; TRIGLYCERIDE PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DIAGNOSTIC PROCEDURE; DIET RESTRICTION; GENETICS; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); POPULATION DISTRIBUTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; AEROBIC EXERCISE; ANTISENSE THERAPY; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG TARGETING; EPIDEMIOLOGICAL DATA; GENE REPLACEMENT THERAPY; GENETIC ASSOCIATION; GENETIC VARIABILITY; MEDITERRANEAN DIET; RISK ASSESSMENT; RISK FACTOR; TREATMENT INDICATION;

ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EXERCISE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; LIFE STYLE; RISK ASSESSMENT; RISK FACTORS;

EID: 84906259943     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61177-6     Document Type: Review

References (80)

1. Recommendations for the treatment of hyperlipidemia in adults A joint statement of the Nutrition Committee and the Council on Arteriosclerosis of the American Heart Association Arteriosclerosis 4 1984 443A 468A
2. Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society Eur Heart J 8 1987 77 88
3. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society Eur Heart J 9 1988 571 600
4. DB Zilversmit Atherogenesis: a postprandial phenomenon Circulation 60 1979 473 485
5. JK Goldstein, HH Hobbs, MS Brown Familial hypercholesterolemia CR Scriver AL Beaudet WS Sly D Valle The Metabolic & Molecular Bases of Inherited Disease 8th edn 2001 McGraw-Hill New York 2863 2913
6. D Steinberg, A Lewis Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis Circulation 95 1997 1062 1071
7. A Endo The discovery and development of HMG-CoA reductase inhibitors J Lipid Res 33 1992 1569 1582
8. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
9. C Baigent, L Blackwell, J Emberson et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
10. A Varbo, M Benn, A Tybjaerg-Hansen, AB Jørgensen, R Frikke-Schmidt, BG Nordestgaard Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 2013 427 436
11. B Agerholm-Larsen, BG Nordestgaard, R Steffensen, G Jensen, A Tybjaerg-Hansen Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene Circulation 101 2000 1907 1912
12. RV Andersen, HH Wittrup, A Tybjaerg-Hansen, R Steffensen, P Schnohr, BG Nordestgaard Hepatic lipase mutations, elevated high-density lipoprotein cholesterol, and increased risk of ischemic heart disease: the Copenhagen City Heart Study J Am Coll Cardiol 41 2003 1972 1982
13. R Frikke-Schmidt, BG Nordestgaard, MC Stene et al. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease JAMA 299 2008 2524 2532
14. CL Haase, A Tybjaerg-Hansen, AA Qayyum, J Schou, BG Nordestgaard, R Frikke-Schmidt LCAT, HDL cholesterol and ischemic cardiovascular disease: a Mendelian randomization study of HDL cholesterol in 54,500 individuals J Clin Endocrinol Metab 97 2012 E248 E256
15. BF Voight, GM Peloso, M Orho-Melander et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 2012 572 580
16. PJ Barter, M Caulfield, M Eriksson et al. Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
17. GG Schwartz, AG Olsson, M Abt et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome N Engl J Med 367 2012 208999
18. WE Boden, JL Probstfield, T Anderson et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
19. HPS2-THRIVE Collaborative Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 2013 1279 1291
20. MJ Landray, R Haynes, JC Hopewell the HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients N Engl J Med 371 2014 203 212
21. MJ Chapman, HN Ginsberg, P Amarenco et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
22. IJ Goldberg, RH Eckel, R McPherson Triglycerides and heart disease: still a hypothesis? Arterioscler Thromb Vasc Biol 31 2011 1716 1725
23. M Miller, NJ Stone, C Ballantyne et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 2011 2292 2333
24. GD Kolovou, DP Mikhailidis, J Kovar et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement Curr Vasc Pharmacol 9 2011 258 270
25. T Gotoda, K Shirai, T Ohta et al. Diagnosis and management of type I and type V hyperlipoproteinemia J Atheroscler Thromb 19 2012 1 12
26. GF Watts, EM Ooi, DC Chan Demystifying the management of hypertriglyceridaemia Nat Rev Cardiol 10 2013 648 661
27. RA Hegele, HN Ginsberg, MJ Chapman et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management Lancet Diabetes Endocrinol 2013 published online Dec 23. http://dx.doi.org/10. 1016/S2213-8587(13)70191-8
28. A Varbo, M Benn, BG Nordestgaard Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment Pharmacol Ther 141 2014 358 367
29. J Boren, N Matikainen, M Adiels, MR Taskinen Postprandial hypertriglyceridemia as a coronary risk factor Clin Chim Acta 431C 2014 131 142
30. JD Brunzell, SS Deeb Familial lipoprotein lipase deficiency, Apo C-II deficiency, and hepatic lipase Deficiency CR Scriver AL Beaudet WS Sly D Valle The Metabolic & Molecular Bases of Inherited Disease 8th edn 2001 McGraw-Hill New York 2789 2816
31. BG Nordestgaard, S Stender, K Kjeldsen Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall Arteriosclerosis 8 1988 421 428
32. BG Nordestgaard, DB Zilversmit Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits J Lipid Res 29 1988 1491 1500
33. M Shaikh, R Wootton, BG Nordestgaard et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans Arterioscler Thromb 11 1991 569 577
34. BG Nordestgaard, A Tybjaerg-Hansen, B Lewis Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants Arterioscler Thromb 12 1992 6 18
35. BG Nordestgaard, R Wootton, B Lewis Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media Arterioscler Thromb Vasc Biol 15 1995 534 542
36. JE Hokanson, MA Austin Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
37. N Sawar, J Danesh, G Eiriksdottir et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies Circulation 115 2007 450 458
38. BG Nordestgaard, M Benn, P Schnohr, A Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
39. S Bansal, JE Buring, N Rifai, S Mora, FM Sacks, PM Ridker Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women JAMA 298 2007 309 316
40. JJ Freiberg, A Tybjaerg-Hansen, JS Jensen, BG Nordestgaard Nonfasting triglycerides and risk of ischemic stroke in the general population JAMA 300 2008 2142 2152
41. E Di Angelantonio, N Sarwar, P Perry et al. Major lipids, apolipoproteins, and risk of vascular disease JAMA 302 2009 1993 2000
42. A Langsted, JJ Freiberg, BG Nordestgaard Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction Circulation 118 2008 2047 2056
43. BG Nordestgaard, A Langsted, JJ Freiberg Nonfasting hyperlipidemia and cardiovascular disease Curr Drug Targets 10 2009 328 335
44. A Langsted, BG Nordestgaard Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study Clin Chem 57 2011 482 489
45. BG Nordestgaard, L Hilsted, S Stender [Plasma lipids in non-fasting patients and signal values of laboratory results] Ugeskr Laeger 171 2009 1093
46. D Sidhu, C Naugler Fasting time and lipid levels in a community-based population: a cross-sectional study Arch Intern Med 172 2012 1707 1710
47. C Mihas, GD Kolovou, DP Mikhailidis et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis Curr Vasc Pharmacol 9 2011 271 280
48. S Mora, N Rifai, JE Buring, PM Ridker Comparison of LDL cholesterol concentrations by Friedewald calculation and direct measurement in relation to cardiovascular events in 27 331 women Clin Chem 55 2009 888 894
49. K Tanno, T Okamura, M Ohsawa et al. Comparison of low-density lipoprotein cholesterol concentrations measured by a direct homogeneous assay and by the Friedewald formula in a large community population Clin Chim Acta 411 2010 1774 1780
50. SS Martin, MJ Blaha, MB Elshazly et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile JAMA 310 2013 2061 2068
51. L Berglund, JD Brunzell, AC Goldberg et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 97 2012 2969 2989
52. AB Jørgensen, R Frikke-Schmidt, AS West, P Grande, BG Nordestgaard, A Tybjaerg-Hansen Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction Eur Heart J 34 2013 1826 1833
53. A Varbo, M Benn, A Tybjaerg-Hansen, BG Nordestgaard Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation Circulation 128 2013 1298 1309
54. SD Proctor, DF Vine, JC Mamo Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis Curr Opin Lipidol 13 2002 461 470
55. V Saraswathi, AH Hasty The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages J Lipid Res 47 2006 1406 1415
56. Rutledge JC, Mullick AE, Gardner G, Goldberg IJ. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ Res 200; 86: 768-73.
57. GD Smith, S Ebrahim Mendelian randomization: prospects, potentials, and limitations Int J Epidemiol 33 2004 30 42
58. M Thomsen, A Varbo, A Tybjaerg-Hansen, BG Nordestgaard Low nonfasting triglycerides and reduced all-cause mortality: a mendelian randomization study Clin Chem 60 2014 737 746
59. N Sarwar, MS Sandhu, SL Ricketts et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies Lancet 375 2010 1634 1639
60. TM Teslovich, K Musunuru, AV Smith et al. Biological, clinical and population relevance of 95 loci for blood lipids Nature 466 2010 707 713
61. R Do, CJ Willer, EM Schmidt et al. Common variants associated with plasma triglycerides and risk for coronary artery disease Nat Genet 45 2013 1345 1352
62. TH Johannsen, R Frikke-Schmidt, J Schou, BG Nordestgaard, A Tybjaerg-Hansen Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects J Am Coll Cardiol 60 2012 2041 2048
63. Z Reiner, AL Catapano, G De Backer et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
64. M Jun, C Foote, J Lv et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis Lancet 375 2010 1875 1884
65. LA Carlson, G Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
66. V Manninen, MO Elo, MH Frick et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study JAMA 260 1988 641 651
67. HB Rubins, SJ Robins, D Collins et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
68. The Bezafibrate Infarction Prevention (BIP) Study group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease Circulation 102 2000 21 27
69. R Scott, R O'Brien, G Fulcher et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study Diabetes Care 32 2009 493 498
70. HN Ginsberg, MB Elam, LC Lovato et al. Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
71. TI Pollin, CM Damcott, H Shen et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection Science 322 2008 1702 1705
72. AB Jørgensen, R Frikke-Schmidt, BG Nordestgaard, A Tybjaerg-Hansen Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 2014 32 41
73. The TG and HDL Working Group of the Exome Sequencing Project NHLaBI Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
74. HH Wittrup, A Tybjaerg-Hansen, BG Nordestgaard Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis Circulation 99 1999 2901 2907
75. JC Cohen, E Boerwinkle, TH Mosley, HH Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
76. M Benn, BG Nordestgaard, P Grande, P Schnohr, A Tybjaerg-Hansen PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses J Am Coll Cardiol 55 2010 2833 2842
77. K Musunuru, JP Pirruccello, R Do et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia N Engl J Med 363 2010 2220 2227
78. US National Library of Medicine. ClinicalTrials.gov. http:// clinicaltrials.gov/ (accessed May 11, 2014).
79. J Perk, G De Backer, H Gohlke et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 33 2012 1635 1701
80. NJ Stone, J Robinson, AH Lichtenstein et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2889 2934